Developer docs
API playgroundTry for free, no card

Search company profiles

Ratio Therapeutics

Full company profile

uuid0000jdl

Namestring
Ratio Therapeutics
Legal namestring
Ratio Therapeutics Inc.
Websiteurl
ratiotx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Ratio Therapeutics is a clinical-stage pharmaceutical company founded in 2021 and headquartered in Boston, Massachusetts, focused on developing targeted radiopharmaceuticals for solid tumors. The company operates a platform-plus-pipeline architecture anchored by two proprietary technologies: the Trillium™ targeting scaffold, which uses mathematical modeling for pharmacokinetic modulation to improve tumor delivery and reduce off-target effects, and the Macropa™ chelator, a best-in-class Actinium-225 chelator enabling rapid room-temperature labeling and improved in vivo stability. Layered on this platform are individual candidates including the lead therapeutic [Ac-225]RTX-2358 (FAP-targeted, currently in the Phase 1/2 ATLAS trial with first cohort dosed December 2025), its companion diagnostic [Cu-64]-LNTH-1363S, a pre-clinical [Lu-177]RTX-2358 variant, an in-licensed Granzyme B PET imaging agent from Merck, and an SSTR2 radiotherapeutic out-licensed to Novartis.

The company operates a pre-commercial, partnership-driven business model. It monetizes its platform through out-licensing arrangements with major pharmaceutical companies, including a Novartis license for the SSTR2 candidate valued at up to $745 million in combined upfront and milestone payments plus tiered royalties, and fully funded development alliances with Bayer and Lantheus. Ratio also generates revenue (or will, in the case of Macropa) through exclusive distribution partnerships such as Macrocyclics' worldwide manufacturing and distribution of Macropa for academic and industry researchers. Operational infrastructure spans a 19,000 sq ft Boston R&D headquarters (opened May 2023), a planned 65,000 sq ft manufacturing facility in Salt Lake City (operational H2 2027), and an ecosystem of CDMO partners (PharmaLogic, Eckert & Ziegler) and isotope suppliers (Nusano, TerraPower Isotopes, Niowave). Total cumulative venture financing exceeds $90 million across seed, Series A, and Series B rounds since 2022, with strategic investor Bristol Myers Squibb participating in the Series B.

Short descriptiontext

Ratio Therapeutics is a Boston-based clinical-stage pharmaceutical company developing targeted radiopharmaceuticals for solid tumors using proprietary Trillium™ pharmacokinetic modulation and Macropa™ Actinium-225 chelator platforms, monetizing via out-licensing deals with Novartis, Bayer, Lantheus, and Merck.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted radiopharmaceuticals, cancer radioligand therapy, actinium-225 chelators, theranostic imaging agents, FAP-targeted therapeutics
Industry2 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Targeted Radiopharmaceuticals (Oncology)
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing and collaboration milestone payments
TypeLicensing Royalties
Description

Receives upfront and potential milestone payments under exclusive worldwide license and collaboration agreements (e.g., Novartis SSTR2 deal up to $745M combined upfront + milestones, plus tiered royalty payments). Pre-revenue clinical-stage company monetizing proprietary platform via out-licensing.

insideprecisionmedicine.com
2Equity financing (venture capital)
TypeTransaction Fee
Description

Multiple funding rounds (seed $20M+ in 2022, Series A $20M in Feb 2023, Series B $50M in Jan 2024) for total raised of over $90M since 2021 launch. Led by Schusterman, Duquesne Capital with participation from PagsGroup, Bristol Myers Squibb, and Cornell CTL.

finsmes.com
3Co-funded development alliances with pharmaceutical partners
TypeManaged Services
Description

Fully funded development alliances with Bayer, Lantheus, and Merck for first-in-human trials (e.g., Lantheus collaboration for Cu-64-LNTH-1363S Phase I; Bayer for radiopharmaceutical development; Merck licensing of Granzyme B imaging agent).

ratiotx.com
4Chelator platform licensing (Macropa)
TypeLicensing Royalties
Description

Exclusive manufacturing and distribution rights granted to Macrocyclics Inc. (subsidiary of Orano Med) for Ratio's proprietary Macropa chelator, enabling researchers from academia and industry to purchase Macropa in Japan, Canada, Australia, and most of Europe.

ratiotx.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Quote-based licensing/collaboration deals (B2B pharma partnerships, not product pricing)
ModelOtherBilling cadenceMulti-year contract
Notes

Novartis deal valued at up to $745 million (combined upfront + milestones) plus tiered royalty payments. Pricing not publicly disclosed for products as company is pre-commercial.

insideprecisionmedicine.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ratio Therapeutics is a clinical-stage pharmaceutical company developing best-in-class targeted radiopharmaceuticals for cancer treatment. Its portfolio is built on two proprietary platforms—Trillium™, a pharmacokinetic modulation targeting scaffold, and Macropa™, a proprietary chelator for Actinium-225 (Ac-225)—and includes the lead FAP-targeted alpha-therapy candidate [Ac-225]RTX-2358 (in the Phase 1/2 ATLAS trial), the companion Cu-64 PET imaging diagnostic [Cu-64]-LNTH-1363S, an in-licensed Granzyme B PET imaging agent, and an SSTR2 radiotherapeutic candidate out-licensed to Novartis. The company monetizes this pipeline primarily through licensing and co-development partnerships with major pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to $745M in combined upfront and milestone payments plus tiered royalties from Novartis license (Nov 2024)
+4 more records
Product overview1 text field

Ratio Therapeutics operates a platform-plus-pipeline architecture rather than a single unified product. The core engine is the Trillium™ proprietary pharmacokinetic modulation platform, which uses mathematical modeling to engineer tumor-targeted radiopharmaceuticals with optimized uptake and clearance. Underpinning the therapeutic side of the platform is Macropa™, Ratio's proprietary Actinium-225 chelator manufactured exclusively with Macrocyclics. Layered on top of Trillium™ are individual product candidates: the lead therapeutic [Ac-225]RTX-2358 (FAP-targeted, currently in the ATLAS Phase 1/2 trial), its companion PET diagnostic [Cu-64]-LNTH-1363S, the pre-clinical beta-emitting variant [Lu-177]RTX-2358, the in-licensed Granzyme B-targeted PET imaging agent from Merck, and the SSTR2 radiotherapeutic candidate out-licensed to Novartis. Together, Trillium™ functions as the platform layer, Macropa™ as the enabling chemistry layer, and the named candidates as the module-level pipeline assets.

Product and service6 records
1Trillium™ targeting scaffold platform
CategoryCore platform technology
Description

A proprietary platform technology (not a standalone sellable offering) that incorporates a tunable structural motif enabling compounds to reversibly bind to albumin, thereby modulating pharmacokinetics and improving drug availability, tumor delivery, and tumor loading while reducing side effects. The Trillium scaffold can be applied to any antigen-specific target and is the foundation for Ratio's therapeutic and diagnostic candidates.

2Macropa™ chelator
CategoryChelation chemistry / Enabling technology
Description

A proprietary best-in-class bifunctional chelator for Actinium-225 (Ac-225), enabling rapid and quantitative complexing at room temperature (one-pot manufacturing) with improved in vivo stability. Compatible with small molecules, peptides, and large polypeptides (including antibodies). Sold/distributed via Macrocyclics to academic and industry radiopharmaceutical researchers.

3[Ac-225]RTX-2358 (FAP-targeted alpha-therapy)
CategoryTherapeutic radiopharmaceutical candidate
Description

Lead therapeutic candidate — an Actinium-225-labeled, fibroblast activation protein (FAP)-targeted therapeutic radiopharmaceutical built on the Trillium™ platform using the Macropa™ chelator. Currently being evaluated in the Phase 1/2 ATLAS clinical trial for patients with relapsed or refractory soft tissue sarcoma, with development for additional FAP-expressing tumors.

4[Cu-64]-LNTH-1363S (FAP-targeted PET imaging diagnostic)
CategoryCompanion diagnostic imaging agent
Description

Copper-64-labeled FAP-targeted PET imaging agent (formerly designated RTX-1363S) designed as the diagnostic companion to Ratio's FAP-targeted therapeutic program. Used for patient selection and treatment planning in the radioligand therapy workflow, particularly for FAP-expressing tumors.

5Granzyme B-targeted PET imaging agent
CategoryIn-licensed diagnostic imaging asset
Description

Granzyme B-targeted PET imaging agent in-licensed from Merck (March 2023), expanding Ratio's radiodiagnostic imaging pipeline and complementing the Trillium™ therapeutic platform with an apoptosis-activity imaging biomarker for monitoring immune cell activation in inflammatory, autoimmune disease, cancer, and infection indications.

6SSTR2 radiotherapeutic candidate
CategoryOut-licensed therapeutic radiopharmaceutical asset
Description

Somatostatin receptor 2 (SSTR2)-targeted radiotherapeutic candidate out-licensed to Novartis (November 2024), applying the Trillium™ pharmacokinetic modulation platform to the validated SSTR2 oncology target. Novartis assumes remaining development, manufacturing, and commercialization under the exclusive worldwide license and collaboration agreement.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCore Supply PartnerTypeStrategic or Co-development PartnerAnnounced on2026-06-16
Description

Supply agreement for cGMP Actinium-225 (signed June 2026). Niowave supplies the radioisotope to support Ratio's development of targeted radiotherapeutics for cancer treatment, providing reliable domestic sourcing for ongoing clinical trials and future program advancement.

Strategic tierCore Supply PartnerTypeStrategic or Co-development PartnerAnnounced on2025-06-20
Description

Supply agreement (Jun 20, 2025) for non-cGMP Actinium-225 (Ac-225) for use in developing Ratio's radiopharmaceuticals. Strengthens ability to scale production and advance Trillium/Macropa platforms for targeted alpha therapies.

Strategic tierCore Supply PartnerTypeStrategic or Co-development PartnerAnnounced on2025-06-17
Description

Long-term multi-isotope supply agreement (Jun 17, 2025) providing commercial-scale access to copper-64 (Cu-64) for PET imaging diagnostics, lutetium-177 (Lu-177) and actinium-225 (Ac-225) for therapeutic applications. Proximity of Nusano's West Valley City, Utah operations to Ratio's planned manufacturing facility streamlines logistics.

Strategic tierCore Chelator Distribution PartnerTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-06-13
Description

Exclusive manufacturing and distribution rights granted (Jun 13, 2025) to Ratio's proprietary Macropa chelator worldwide. Macrocyclics is a CDMO specializing in chelating agents for radiopharmaceuticals, founded 1995, based in Plano, Texas. Researchers from academia and industry can purchase Macropa directly in Japan, Canada, Australia, and majority of Europe.

Strategic tierCore Facility PartnerTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

Agreement with Medical Innovation Technology Management (MIT) division of Wasatch Group to construct a 65,000 sq ft state-of-the-art radiopharmaceutical research and manufacturing facility in Salt Lake City, Utah. First tenant in Wasatch's Medical Innovation Technology Research Campus. Facility anticipated fully operational H2 2027.

Strategic tierFlagship / Top-TierTypeStrategic or Co-development PartnerAnnounced on2024-11-18
Description

Exclusive worldwide license and collaboration agreement for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. Novartis assumes responsibility for all remaining development, manufacturing, and commercialization. Deal valued at up to $745M in combined upfront and milestone payments, plus tiered royalties. Chestnut Partners served as exclusive financial advisor to Ratio.

Strategic tierFlagship / Core Manufacturing PartnerTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-03-12
Description

Contract development and manufacturing organization (CDMO) partner for radiopharmaceuticals. Multiple expansions: March 2024 (manufacturing agreement for FAP-targeted radiopharmaceuticals), Dec 2025 (successful supply of first ATLAS trial cohort at Bronx facility), May 2026 (expanded to Idaho Falls facility for larger multi-dose batch manufacturing of [Ac-225]RTX-2358 to support later-stage and registrational trials).

Strategic tierFlagship / Top-Tier Clinical PartnerTypeStrategic or Co-development PartnerAnnounced on2023-07-11
Description

Collaboration partner for FAP-targeted radiopharmaceuticals — provided Cu-64-LNTH-1363S for Phase I PET imaging study in epithelial-derived cancers (initiated dosing July 2023) and supplied [Cu-64]-LNTH-1363S for ATLAS trial. Co-developing companion diagnostic for Ratio's FAP-targeted therapeutic. Partnership since Ratio's 2022 launch.

Strategic tierFlagship / Tier-1 Pharma PartnerTypeStrategic or Co-development PartnerAnnounced on2023-03-28
Description

Licensing agreement (Mar 28, 2023) — Merck provided Ratio with several candidates and supporting preclinical/CMC data of Granzyme B-targeted agent for PET imaging applications. Ratio responsible for clinical development and building GMP production network across North America, Western Europe, Japan, Australia. Granzyme B agent expected to move into clinic in 2026.

Strategic tierMinor / Early-Stage Contract ManufacturerTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-07-06
Description

Contract manufacturer agreement (Jul 6, 2022) for joint development and manufacture of innovative radiopharmaceutical products based on Lutetium-177 and Actinium-225. Covers development of validated manufacturing process and GMP-compliant production of clinical investigational candidates.

Strategic tierFlagship / Tier-1 Pharma PartnerTypeStrategic or Co-development PartnerAnnounced on2022-06-10
Description

Fully funded development alliance (since June 2022 launch) for radiopharmaceutical development. Ratio's Trillium platform reportedly 'caught the eye of Bayer' for enhancing radioligand pharmacokinetics and bioavailability while reducing side effects.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Listed once above as the closest direct peer; included a second time is an error and should be deduplicated.

TypeEmerging player
Description

Pre-clinical radiopharmaceutical company engineering targeted alpha and beta therapies for cancer. Comparable as an early-stage radiopharma peer featured alongside Ratio and Perspective in industry pre-clinical RLT cohorts.

3PharmaLogic Holdings
TypeOthers
Description

Radiopharmaceutical CDMO manufacturing Ratio's clinical supply (including first ATLAS cohort at its Bronx facility, expanded to Idaho Falls). Comparable as a key infrastructure partner and as a fellow radiopharma ecosystem enabler.

TypeDirect peer
Description

Established radiopharmaceutical company with commercial diagnostic products (Pylarify, Definity) and an emerging therapeutic pipeline. Directly comparable as Ratio's clinical partner on Cu-64-LNTH-1363S and as a fellow FAP/SSTR2-area radioligand developer.

TypeBroad incumbent
Description

Radiopharmaceutical developer acquired by Eli Lilly in 2023; focused on next-generation alpha and beta-emitting RLTs for solid tumors. Comparable as a well-capitalized, solid-tumor-focused radiopharma platform now backed by a top-5 pharma.

TypeDirect peer
Description

Clinical/commercial radiopharmaceutical company developing targeted diagnostic and therapeutic agents for oncology (e.g., Illuccix for PSMA imaging, TLX591/TLX250 pipelines). Directly comparable as a theranostics platform player with overlapping alpha/beta emitter programs; Ratio's newly appointed CMO Colin Hayward joined from Telix.

TypeOthers
Description

Specialist isotope and contract manufacturer for radiopharmaceuticals (Lu-177, Ac-225) with GMP production. Comparable as a manufacturing and isotope supply partner to Ratio and as a fellow radiopharma infrastructure provider.

TypeEmerging player
Description

Clinical-stage radiopharma developing targeted alpha and beta therapies (Pb-212, Lu-177) for solid tumors. Comparable as a pre-commercial emerging peer featured alongside Ratio at JPM/Sachs Oncology, sharing a focus on solid-tumor alpha-emitter approaches.

TypeBroad incumbent
Description

Global pharma that built the radioligand therapy category via Pluvicto and Lutathera (acquired with Advanced Accelerator Applications). Directly comparable as a major incumbent pursuing SSTR2 and solid-tumor RLTs; also Ratio's $745M SSTR2 licensee.

TypeBroad incumbent
Description

Diversified life sciences incumbent with an active radiopharmaceuticals strategy (including Nubeqa/Albira, Curium/PMB acquisitions). Comparable as a large-pharma platform player with funded alliance history against Ratio's Trillium platform since 2022.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ratio Therapeutics

Targeted Radiopharmaceuticals (Oncology)ratiotx.com

Ratio Therapeutics is a Boston-based clinical-stage pharmaceutical company developing targeted radiopharmaceuticals for solid tumors using proprietary Trillium™ pharmacokinetic modulation and Macropa™ Actinium-225 chelator platforms, monetizing via out-licensing deals with Novartis, Bayer, Lantheus, and Merck.

What Ratio Therapeutics does

Ratio Therapeutics is a clinical-stage pharmaceutical company founded in 2021 and headquartered in Boston, Massachusetts, focused on developing targeted radiopharmaceuticals for solid tumors. The company operates a platform-plus-pipeline architecture anchored by two proprietary technologies: the Trillium™ targeting scaffold, which uses mathematical modeling for pharmacokinetic modulation to improve tumor delivery and reduce off-target effects, and the Macropa™ chelator, a best-in-class Actinium-225 chelator enabling rapid room-temperature labeling and improved in vivo stability. Layered on this platform are individual candidates including the lead therapeutic [Ac-225]RTX-2358 (FAP-targeted, currently in the Phase 1/2 ATLAS trial with first cohort dosed December 2025), its companion diagnostic [Cu-64]-LNTH-1363S, a pre-clinical [Lu-177]RTX-2358 variant, an in-licensed Granzyme B PET imaging agent from Merck, and an SSTR2 radiotherapeutic out-licensed to Novartis.

The company operates a pre-commercial, partnership-driven business model. It monetizes its platform through out-licensing arrangements with major pharmaceutical companies, including a Novartis license for the SSTR2 candidate valued at up to $745 million in combined upfront and milestone payments plus tiered royalties, and fully funded development alliances with Bayer and Lantheus. Ratio also generates revenue (or will, in the case of Macropa) through exclusive distribution partnerships such as Macrocyclics' worldwide manufacturing and distribution of Macropa for academic and industry researchers. Operational infrastructure spans a 19,000 sq ft Boston R&D headquarters (opened May 2023), a planned 65,000 sq ft manufacturing facility in Salt Lake City (operational H2 2027), and an ecosystem of CDMO partners (PharmaLogic, Eckert & Ziegler) and isotope suppliers (Nusano, TerraPower Isotopes, Niowave). Total cumulative venture financing exceeds $90 million across seed, Series A, and Series B rounds since 2022, with strategic investor Bristol Myers Squibb participating in the Series B.

Ratio Therapeutics firmographics

Firmographics
Name
Ratio Therapeutics
Legal name
Ratio Therapeutics Inc.
Website
https://ratiotx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Ratio Therapeutics is a Boston-based clinical-stage pharmaceutical company developing targeted radiopharmaceuticals for solid tumors using proprietary Trillium™ pharmacokinetic modulation and Macropa™ Actinium-225 chelator platforms, monetizing via out-licensing deals with Novartis, Bayer, Lantheus, and Merck.
Ownership category
akta.pro rank

Ratio Therapeutics industry classification

Industry
Product category
Targeted Radiopharmaceuticals (Oncology)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Targeted radiopharmaceuticals
  • Cancer radioligand therapy
  • Actinium-225 chelators
  • Theranostic imaging agents
  • FAP-targeted therapeutics

Where Ratio Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Ratio Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing and collaboration milestone payments: Receives upfront and potential milestone payments under exclusive worldwide license and collaboration agreements (e.g., Novartis SSTR2 deal up to $745M combined upfront + milestones, plus tiered royalty payments). Pre-revenue clinical-stage company monetizing proprietary platform via out-licensing.
  2. Equity financing (venture capital): Multiple funding rounds (seed $20M+ in 2022, Series A $20M in Feb 2023, Series B $50M in Jan 2024) for total raised of over $90M since 2021 launch. Led by Schusterman, Duquesne Capital with participation from PagsGroup, Bristol Myers Squibb, and Cornell CTL.
  3. Co-funded development alliances with pharmaceutical partners: Fully funded development alliances with Bayer, Lantheus, and Merck for first-in-human trials (e.g., Lantheus collaboration for Cu-64-LNTH-1363S Phase I; Bayer for radiopharmaceutical development; Merck licensing of Granzyme B imaging agent).
  4. Chelator platform licensing (Macropa): Exclusive manufacturing and distribution rights granted to Macrocyclics Inc. (subsidiary of Orano Med) for Ratio's proprietary Macropa chelator, enabling researchers from academia and industry to purchase Macropa in Japan, Canada, Australia, and most of Europe.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based licensing/collaboration deals (B2B pharma partnerships, not product pricing)

Go-to-market motion3 records

Distribution channels1 record

Marketing channels9 records

Ratio Therapeutics product offering

Product offering

Core offering

Ratio Therapeutics is a clinical-stage pharmaceutical company developing best-in-class targeted radiopharmaceuticals for cancer treatment. Its portfolio is built on two proprietary platforms—Trillium™, a pharmacokinetic modulation targeting scaffold, and Macropa™, a proprietary chelator for Actinium-225 (Ac-225)—and includes the lead FAP-targeted alpha-therapy candidate [Ac-225]RTX-2358 (in the Phase 1/2 ATLAS trial), the companion Cu-64 PET imaging diagnostic [Cu-64]-LNTH-1363S, an in-licensed Granzyme B PET imaging agent, and an SSTR2 radiotherapeutic candidate out-licensed to Novartis. The company monetizes this pipeline primarily through licensing and co-development partnerships with major pharmaceutical companies.

Product overview

Ratio Therapeutics operates a platform-plus-pipeline architecture rather than a single unified product. The core engine is the Trillium™ proprietary pharmacokinetic modulation platform, which uses mathematical modeling to engineer tumor-targeted radiopharmaceuticals with optimized uptake and clearance. Underpinning the therapeutic side of the platform is Macropa™, Ratio's proprietary Actinium-225 chelator manufactured exclusively with Macrocyclics. Layered on top of Trillium™ are individual product candidates: the lead therapeutic [Ac-225]RTX-2358 (FAP-targeted, currently in the ATLAS Phase 1/2 trial), its companion PET diagnostic [Cu-64]-LNTH-1363S, the pre-clinical beta-emitting variant [Lu-177]RTX-2358, the in-licensed Granzyme B-targeted PET imaging agent from Merck, and the SSTR2 radiotherapeutic candidate out-licensed to Novartis. Together, Trillium™ functions as the platform layer, Macropa™ as the enabling chemistry layer, and the named candidates as the module-level pipeline assets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Trillium™ targeting scaffold platform A proprietary platform technology (not a standalone sellable offering) that incorporates a tunable structural motif enabling compounds to reversibly bind to albumin, thereby modulating pharmacokinetics and improving drug availability, tumor delivery, and tumor loading while reducing side effects. The Trillium scaffold can be applied to any antigen-specific target and is the foundation for Ratio's therapeutic and diagnostic candidates.
  • Macropa™ chelator A proprietary best-in-class bifunctional chelator for Actinium-225 (Ac-225), enabling rapid and quantitative complexing at room temperature (one-pot manufacturing) with improved in vivo stability. Compatible with small molecules, peptides, and large polypeptides (including antibodies). Sold/distributed via Macrocyclics to academic and industry radiopharmaceutical researchers.
  • [Ac-225]RTX-2358 (FAP-targeted alpha-therapy) Lead therapeutic candidate — an Actinium-225-labeled, fibroblast activation protein (FAP)-targeted therapeutic radiopharmaceutical built on the Trillium™ platform using the Macropa™ chelator. Currently being evaluated in the Phase 1/2 ATLAS clinical trial for patients with relapsed or refractory soft tissue sarcoma, with development for additional FAP-expressing tumors.
  • [Cu-64]-LNTH-1363S (FAP-targeted PET imaging diagnostic) Copper-64-labeled FAP-targeted PET imaging agent (formerly designated RTX-1363S) designed as the diagnostic companion to Ratio's FAP-targeted therapeutic program. Used for patient selection and treatment planning in the radioligand therapy workflow, particularly for FAP-expressing tumors.
  • Granzyme B-targeted PET imaging agent Granzyme B-targeted PET imaging agent in-licensed from Merck (March 2023), expanding Ratio's radiodiagnostic imaging pipeline and complementing the Trillium™ therapeutic platform with an apoptosis-activity imaging biomarker for monitoring immune cell activation in inflammatory, autoimmune disease, cancer, and infection indications.
  • SSTR2 radiotherapeutic candidate Somatostatin receptor 2 (SSTR2)-targeted radiotherapeutic candidate out-licensed to Novartis (November 2024), applying the Trillium™ pharmacokinetic modulation platform to the validated SSTR2 oncology target. Novartis assumes remaining development, manufacturing, and commercialization under the exclusive worldwide license and collaboration agreement.

Quantifiable outcome

  • Up to $745M in combined upfront and milestone payments plus tiered royalties from Novartis license (Nov 2024)
  • +4 more outcomes

Companies that use Ratio Therapeutics

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Ratio Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Ratio Therapeutics partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core supply partner, core chelator distribution partner, core facility partner, flagship / top-tier, flagship / core manufacturing partner, flagship / top-tier clinical partner, flagship / tier-1 pharma partner and minor / early-stage contract manufacturer.

  • Niowave, Inc.core supply partnerStrategic or Co-development Partner · 16 June 2026Supply agreement for cGMP Actinium-225 (signed June 2026). Niowave supplies the radioisotope to support Ratio's development of targeted radiotherapeutics for cancer treatment, providing reliable domestic sourcing for ongoing clinical trials and future program advancement.
  • TerraPower Isotopescore supply partnerStrategic or Co-development Partner · 20 June 2025Supply agreement (Jun 20, 2025) for non-cGMP Actinium-225 (Ac-225) for use in developing Ratio's radiopharmaceuticals. Strengthens ability to scale production and advance Trillium/Macropa platforms for targeted alpha therapies.
  • Nusanocore supply partnerStrategic or Co-development Partner · 17 June 2025Long-term multi-isotope supply agreement (Jun 17, 2025) providing commercial-scale access to copper-64 (Cu-64) for PET imaging diagnostics, lutetium-177 (Lu-177) and actinium-225 (Ac-225) for therapeutic applications. Proximity of Nusano's West Valley City, Utah operations to Ratio's planned manufacturing facility streamlines logistics.
  • Macrocyclics Inc. (Orano Med subsidiary)core chelator distribution partnerOEM/ Whitelabel/ Licensing Partner · 13 June 2025Exclusive manufacturing and distribution rights granted (Jun 13, 2025) to Ratio's proprietary Macropa chelator worldwide. Macrocyclics is a CDMO specializing in chelating agents for radiopharmaceuticals, founded 1995, based in Plano, Texas. Researchers from academia and industry can purchase Macropa directly in Japan, Canada, Australia, and majority of Europe.
  • Wasatch Group (MIT Management division)core facility partnerStrategic or Co-development Partner · 8 May 2025Agreement with Medical Innovation Technology Management (MIT) division of Wasatch Group to construct a 65,000 sq ft state-of-the-art radiopharmaceutical research and manufacturing facility in Salt Lake City, Utah. First tenant in Wasatch's Medical Innovation Technology Research Campus. Facility anticipated fully operational H2 2027.
  • Novartis Pharma AGflagship / top-tierStrategic or Co-development Partner · 18 November 2024Exclusive worldwide license and collaboration agreement for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. Novartis assumes responsibility for all remaining development, manufacturing, and commercialization. Deal valued at up to $745M in combined upfront and milestone payments, plus tiered royalties. Chestnut Partners served as exclusive financial advisor to Ratio.
  • PharmaLogic Holdings Corp.flagship / core manufacturing partnerImplementation/ SI/ Consulting Partner · 12 March 2024Contract development and manufacturing organization (CDMO) partner for radiopharmaceuticals. Multiple expansions: March 2024 (manufacturing agreement for FAP-targeted radiopharmaceuticals), Dec 2025 (successful supply of first ATLAS trial cohort at Bronx facility), May 2026 (expanded to Idaho Falls facility for larger multi-dose batch manufacturing of [Ac-225]RTX-2358 to support later-stage and registrational trials).
  • Lantheusflagship / top-tier clinical partnerStrategic or Co-development Partner · 11 July 2023Collaboration partner for FAP-targeted radiopharmaceuticals — provided Cu-64-LNTH-1363S for Phase I PET imaging study in epithelial-derived cancers (initiated dosing July 2023) and supplied [Cu-64]-LNTH-1363S for ATLAS trial. Co-developing companion diagnostic for Ratio's FAP-targeted therapeutic. Partnership since Ratio's 2022 launch.
  • Merck (MSD outside U.S./Canada)flagship / tier-1 pharma partnerStrategic or Co-development Partner · 28 March 2023Licensing agreement (Mar 28, 2023) — Merck provided Ratio with several candidates and supporting preclinical/CMC data of Granzyme B-targeted agent for PET imaging applications. Ratio responsible for clinical development and building GMP production network across North America, Western Europe, Japan, Australia. Granzyme B agent expected to move into clinic in 2026.
  • Eckert & Zieglerminor / early-stage contract manufacturerImplementation/ SI/ Consulting Partner · 6 July 2022Contract manufacturer agreement (Jul 6, 2022) for joint development and manufacture of innovative radiopharmaceutical products based on Lutetium-177 and Actinium-225. Covers development of validated manufacturing process and GMP-compliant production of clinical investigational candidates.
  • Bayerflagship / tier-1 pharma partnerStrategic or Co-development Partner · 10 June 2022Fully funded development alliance (since June 2022 launch) for radiopharmaceutical development. Ratio's Trillium platform reportedly 'caught the eye of Bayer' for enhancing radioligand pharmacokinetics and bioavailability while reducing side effects.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Ratio Therapeutics competitors and assessment

Company assessment

Direct peers

  • Telix Pharmaceuticals: Listed once above as the closest direct peer; included a second time is an error and should be deduplicated.
  • Lantheus Holdings: Established radiopharmaceutical company with commercial diagnostic products (Pylarify, Definity) and an emerging therapeutic pipeline. Directly comparable as Ratio's clinical partner on Cu-64-LNTH-1363S and as a fellow FAP/SSTR2-area radioligand developer.
  • Telix Pharmaceuticals: Clinical/commercial radiopharmaceutical company developing targeted diagnostic and therapeutic agents for oncology (e.g., Illuccix for PSMA imaging, TLX591/TLX250 pipelines). Directly comparable as a theranostics platform player with overlapping alpha/beta emitter programs; Ratio's newly appointed CMO Colin Hayward joined from Telix.

Emerging players

  • Abdera Therapeutics: Pre-clinical radiopharmaceutical company engineering targeted alpha and beta therapies for cancer. Comparable as an early-stage radiopharma peer featured alongside Ratio and Perspective in industry pre-clinical RLT cohorts.
  • Perspective Therapeutics: Clinical-stage radiopharma developing targeted alpha and beta therapies (Pb-212, Lu-177) for solid tumors. Comparable as a pre-commercial emerging peer featured alongside Ratio at JPM/Sachs Oncology, sharing a focus on solid-tumor alpha-emitter approaches.

Others

  • PharmaLogic Holdings: Radiopharmaceutical CDMO manufacturing Ratio's clinical supply (including first ATLAS cohort at its Bronx facility, expanded to Idaho Falls). Comparable as a key infrastructure partner and as a fellow radiopharma ecosystem enabler.
  • Eckert & Ziegler: Specialist isotope and contract manufacturer for radiopharmaceuticals (Lu-177, Ac-225) with GMP production. Comparable as a manufacturing and isotope supply partner to Ratio and as a fellow radiopharma infrastructure provider.

Broad incumbents

  • Point Biopharma (Lilly): Radiopharmaceutical developer acquired by Eli Lilly in 2023; focused on next-generation alpha and beta-emitting RLTs for solid tumors. Comparable as a well-capitalized, solid-tumor-focused radiopharma platform now backed by a top-5 pharma.
  • Novartis (Radioligand Therapy / Pluvicto & Lutathera): Global pharma that built the radioligand therapy category via Pluvicto and Lutathera (acquired with Advanced Accelerator Applications). Directly comparable as a major incumbent pursuing SSTR2 and solid-tumor RLTs; also Ratio's $745M SSTR2 licensee.
  • Bayer (Radiopharmaceuticals): Diversified life sciences incumbent with an active radiopharmaceuticals strategy (including Nubeqa/Albira, Curium/PMB acquisitions). Comparable as a large-pharma platform player with funded alliance history against Ratio's Trillium platform since 2022.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Ratio Therapeutics social profiles

Digital presence

Ratio Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ratio Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Ratio Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ratio Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ratio Therapeutics

What does Ratio Therapeutics do?

Ratio Therapeutics is a clinical-stage pharmaceutical company developing best-in-class targeted radiopharmaceuticals for cancer treatment. Its portfolio is built on two proprietary platforms—Trillium™, a pharmacokinetic modulation targeting scaffold, and Macropa™, a proprietary chelator for Actinium-225 (Ac-225)—and includes the lead FAP-targeted alpha-therapy candidate [Ac-225]RTX-2358 (in the Phase 1/2 ATLAS trial), the companion Cu-64 PET imaging diagnostic [Cu-64]-LNTH-1363S, an in-licensed Granzyme B PET imaging agent, and an SSTR2 radiotherapeutic candidate out-licensed to Novartis. The company monetizes this pipeline primarily through licensing and co-development partnerships with major pharmaceutical companies.

Is Ratio Therapeutics a public or private company?

Ratio Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ratio Therapeutics founded?

Ratio Therapeutics was founded in 2021. It employs 51 to 100 people.

Where is Ratio Therapeutics based?

Ratio Therapeutics is headquartered in Boston, United States, in the North America region.

How does Ratio Therapeutics make money?

Four revenue lines are on record. Licensing and collaboration milestone payments are the primary driver. The others are equity financing (venture capital), co-funded development alliances with pharmaceutical partners and chelator platform licensing (Macropa).

Who are Ratio Therapeutics's main competitors?

Direct peers on record are Telix Pharmaceuticals, Lantheus Holdings and Telix Pharmaceuticals. Emerging players are Abdera Therapeutics and Perspective Therapeutics. Others are PharmaLogic Holdings and Eckert & Ziegler. Broad incumbents are Point Biopharma (Lilly), Novartis (Radioligand Therapy / Pluvicto & Lutathera) and Bayer (Radiopharmaceuticals).

Does Ratio Therapeutics have an API?

No public API is recorded for Ratio Therapeutics.

What industry is Ratio Therapeutics in?

Ratio Therapeutics's product category is Targeted Radiopharmaceuticals (Oncology). Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRatio Therapeutics Announces the Appointment of Kenan Turnacioglu to its Board of DirectorsRatio Therapeutics appointed Kenan Turnacioglu, Ph.D., to its Board of Directors. He brings over two decades of healthcare investing and biotechnology experience, including current board roles at Immunai, Massive Bio, and Sentonix. He expressed excitement about the company's focus on radiopharmaceutical challenges.PR NewswireRatio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical ProgramRatio Therapeutics entered a research collaboration and license agreement with RayzeBio to advance a novel radiopharmaceutical program targeting two undisclosed targets. Ratio will receive an upfront payment and is eligible for development, regulatory, commercial milestones, and royalties. RayzeBio will hold an exclusive worldwide license and assume responsibility for further development, manufacturing, and commercialization.Phirda融资21亿元:礼来为何押注这家核药公司?In July, biotech financing totaled $166.5M across 15 deals, with nuclear medicine and AI drug discovery leading. LEO Pharma backed AdvanCell's $315M D-round, expanding its partnership for alpha-particle therapies. Other notable rounds included Chai Discovery's $400M C-round and Celea's $100M funding.pharmaphorumLifeMine gets $263m for transplant drug, and other financingsLifeMine Therapeutics raised $263 million in a dual financing to advance its transplant drug LIFE-001 into mid-stage trials. The company will start a phase 2 trial in kidney transplant patients and a phase 1b study in islet cell transplants. The financing is led by Milky Way Investments with new investors including Bezos Expeditions and Gates Frontier.Pulse 2.0Ratio Therapeutics Raises $70 Million Series C To Advance Radiopharmaceutical PipelineRatio Therapeutics raised $70 million in Series C funding to advance its targeted radiopharmaceutical pipeline and expand manufacturing infrastructure, with participation from Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. The financing will support the ATLAS Phase 1/2 study evaluating lead candidate [Ac-225]RTX-2358 in advanced sarcomas, a next-generation radioligand therapy candidate, and preparation for the company's fifth investigational new drug application. The funding brings Ratio's total capital raised to more than $240 million and will enable expansion of manufacturing capabilities to meet clinical and potential commercial demand.The Pharma LetterRatio Therapeutics raises $70 million for radiopharma pipelineUS radiopharmaceutical developer Ratio Therapeutics has closed a $70 million Series C financing round backed by new and existing healthcare investors. The proceeds will advance the company's targeted radiotherapy pipeline through clinical development and expand manufacturing capacity for future trial and commercial supply. This funding represents a significant capital injection to support the progression of Ratio's lead clinical candidates.YahooRatio Therapeutics secures $70m Series C funding for cancer radiotherapyRatio Therapeutics, a US-based clinical-stage radiopharmaceutical developer, has closed a $70 million Series C financing round with participation from existing investors Duquesne Family Office and Bristol Myers Squibb, alongside new investors Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. The funding will support advancement of the ATLAS Phase I/II clinical trial for lead candidate [Ac-225]RTX-2358 in advanced sarcomas, move a next-generation radioligand therapy into clinical studies, and scale manufacturing capabilities. The company, which has a collaboration with Novartis in radioligand therapy, expects the investment to enable pipeline expansion across additional cancer targets and tumour types.YahooRatio Therapeutics secures $70m Series C funding for cancer radiotherapyRatio Therapeutics, a US-based clinical-stage radiopharmaceutical developer for cancer treatment, has closed a $70 million Series C financing round with participation from existing investors Duquesne Family Office and Bristol Myers Squibb, alongside new investors Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. The funding will advance the company's ATLAS Phase I/II clinical trial evaluating its lead candidate [Ac-225]RTX-2358, a fibroblast activation protein-targeted radiotherapeutic for advanced sarcomas, and support next-generation radioligand therapy candidates. Ratio Therapeutics also plans to expand its discovery pipeline to additional cancer targets and scale its proprietary manufacturing capabilities.citybizCatalio Capital Joins $70M Series C for Oncology Startup Ratio TherapeuticsBoston-based clinical-stage pharmaceutical company Ratio Therapeutics has closed a $70 million Series C financing round to advance its ongoing ATLAS Phase 1/2 trial for its lead therapeutic program targeting fibroblast activation protein (FAP), a protein found in cancer-associated fibroblasts. The round included existing investors Duquesne Family Office and Bristol Myers Squibb, alongside new investors Catalio Capital Management, Eli Lilly and Co., and Wasatch Group. Ratio Therapeutics holds an exclusive worldwide license and collaboration agreement with Novartis Pharma AG covering its radioligand therapy discovery and technology platforms.